INTRODUCTION:

Inflammation is an immune system’s response to an irritant. To get rid of the offending irritant and restore the injured tissue, it involves a sequence of changes in the terminal vascular bed, blood, and connective tissues. An inflammatory response occurs in three phases: An acute phase involving local vasodilation, subacute phase categorized by infiltration of phagocytic cells and lastly a chronic proliferative phase resulting in tissue degeneration and fibrosis.

These phases lead to cardinal signs of inflammation: 1. Vasodilation causes the capillary network to swell and carry blood away from the afflicted location, which causes erythema. 2. Increased capillary permeability aids in the movement of fluid and cells out of engorged capillaries and into the tissue. As the exudate builds up, edema develops. 3. Through diapedesis or extravasation, phagocytes move from the capillary endothelial cells into the tissue and eventually to the invasion site (chemotaxis). Lysogenic enzymes are released when phagocytic cells gather at the site and begin to phagocytose foreign particles, which might harm neighboring healthy cells. Natural immuno enhancers stimulate and maintain the immune system¹.

CONGREGATION OF IMMUNITY:

Nitric oxide (NO) is produced as a result of the interaction between inflammatory chemicals and inducible nitric oxide synthase (iNOS). Additionally, studies show that the biology of beta cells may directly influence the response to an inflammatory environment by changing the IFN-gamma-induced beta cell death through specific gene-guided control of the PTPN2 gene. Chemokines are produced at the site of inflammation and establish a concentration gradient to guide the neutrophils and activate the adhesion molecules on the surface of neutrophils. Different cells go to various locations in a fairly particular order: neutrophils arrive during the first 24hours, followed by macrophages and lymphocytes. Most invaders are eliminated by neutrophils. The acquired immunity creates antibodies, cytokines and memory cells, it gets started by macrophages in the early phases of inflammation by eliminating the invaders that have escaped the neutrophils and presenting antigen to T lymphocytes. Further, macrophage pro-inflammatory nature changes to anti-inflammatory to achieve healing. Proinflammation / inflammation is referred as type 1 inflammation while type 2 inflammation has anti-inflammation assets. Type 1 immunity is protective² and is mediated by T helper-1 lymphocytes with intense phagocytic activity (Table 1). Type 2 response serves to resolve inflammation and involves T helper-2 cells stimulated high antibody titers.

Table 1: Comparison of Type 1 and Type 2 Inflammation

Features	Type 1 inflammation	Type 2 inflammation
Motivations	Lipopolysaccharide, Interferon-γ, Tumor necrosis factor-α, Interleukin-12	Interleukin-10, Interleukin-4/Interleukin-13, Allergens
Key cells	T helper-1 cells, M1-macrophages, Neutrophils	T helper-2 cells, M2-macrophages, Eosinophils, Innate lymphoid cells-2
Major tasks	Confrontation with intracellular pathogens	Immunoregulation, Tissue remodeling, Allergy, Shield against extracellular parasites

Association of Immunity Indicators And Diabetes:

Immune activity may be modulated by both low and high glycemic circumstances, and immune cells have high bioenergetics³. Energy production is enhanced by beta-oxidation and mitochondrial activity. When there is an infection, mitochondria emit chemicals called mitochondrial danger associated molecules (DAMPs) that match the molecular patterns associated with bacteria-derived pathogens (PAMPs). Pathogen-fighting inflammation is steered by DAMPs. When mitochondrial DAMPs are generated without an infection present, they cause an unwelcome inflammatory reaction that harms the biological system. Immunological cells have therefore developed defenses against the unwanted immune activation caused by mitochondrial components⁴. The interaction of diabetes and oxidative stress enhances mitochondrial membrane permeability and apoptosis. Diabetes patients' lowered immunity causes an increase in mortality and morbidity⁵. Obese people and people with type 2 diabetes have considerably decreased T helper-1/T helper-2 ratios⁶. Complement tumour necrosis factor related protein-5 (CTRP5) may have a role in the inflammatory process that underlies diabetes and atherosclerosis⁷. Adipokines, chemokines, and a reduction in interleukin-4 all results in T2DM and reduced renal function⁸, which is a major predictor of renal failure. Humoral immune response (immunoglobulin-A, immunoglobulin-G and immunoglobulin-M) and complements are depressed significantly in type 2 diabetic patients which might explain the cause behind recurrent infection in type 2 diabetic patients⁹. Lower incidence of type 2 diabetes is related with higher numbers of CD19⁺CD27⁺ memory B cells¹⁰. Despite having optimum (70mg/dL) management of low density lipoprotein cholesterol (LDL-C), residual inflammatory risk is indicated by circulating levels of high sensitivity C-reactive protein > 2mg/L. In individuals with type 2 diabetes and LDL-C 70mg/dL, glycemic management, insulin resistance, non-LDL-C lipid factors, and central obesity may contribute to residual inflammatory risk¹¹. Complement proteins (Table 2) have been well known to cause a substantial impact on diabetes¹².

Table 2: Role of complement protein in diabetes

Complement protein	Impact on Diabetes
C3	Proinflammatory cytokines are released.
C3a	C3a augments insulin secretion.
C3adesArg (Acylation stimulating factor)	Stimulates uptake of glucose by adipose tissue.
sC5b-9	Elevated in type 2 diabetes. Contributing to endothelial dysfunction and reactive oxygen species.
C5a	Affect coagulation and contribute to inflammation
CD 59	Decreased levels of CD 59 in diabetics.
Membrane attack complex	Increased levels of membrane attack complex contribute to the pathophysiology of diabetic complications

Thus, deregulated immune response serves as a risk factor for diabetes¹³. Patients with type 2 diabetes mellitus have considerably greater levels of neutrophils, vascular cell adhesion molecule-1, and plasminogen activator inhibitor-1 than do healthy individuals. Increased prothrombin time activity and greater concentrations of E- and P-selectin¹⁴ are linked to poor glycemic management. The resident immune cells in visceral adipose tissue are affected by the ketogenic diet, and this has an impact on the body's overall metabolic homeostasis¹⁵. Diabetes patients' periodontiums include higher quantities of glucose and advanced glycation end products, which promote inflammatory cytokine expression¹⁶ and alter the cytomorphology of oral mucosal cells¹⁷. Metabolic endotoxemia and low-grade inflammation are promoted by gut bacteria and microbial products¹⁸. Bacteria cause and maintain localised subclinical inflammation in adipose tissue, which has an effect on the metabolic aftereffects of obesity¹⁹.

IMMUNITY DRIVEN DIABETES COMPLICATIONS:

Anhedonia is a symptom of severe depressive illness and is a result of the interactions between inflammation and metabolic changes that lead to insulin resistance²⁰. Patients with diabetic nephropathy have increased malondialdehyde, glutathione, catalase, and superoxide dismutase activity²¹. Diabetes negatively affects the spleen's ability to operate and retain its structure²². By lowering CD4⁺ T-cell²³ levels, type 2 diabetes patients are at a lower risk of developing cardiovascular disease. It is possible that inflammation and immune response activation contribute to the development of metabolic disorders. Immunometabolism is a disease-development mechanism that is driven by inflammation and/or metabolic processes that promote the cellular differentiation of immune components²⁴. Immune, metabolic, oxidative stress pathways are involved in acute ischemic stroke²⁵. Myeloid cells enter into a metabolically stressed disease environment and activate endoplasmic reticulum²⁶, this further contributes to type 2 diabetes mellitus via protein kinase RNA- like endoplasmic reticulum kinase - eukaryotic initiation factor 2α²⁷. Immunoregulatory functions of metabolites such as succinate, itaconate, α-ketoglutarate and lactate establish parallels and interactions between metabolites and cytokines²⁸. Thus immune response has a prominent impact on type 2 diabetes via direct and indirect routes.

Neuroinflammation and neuro-oxidative stress, which are pathophysiological causes in diabetic insensate neuropathy, are mediated by T immune cells. Diabetes-related behavioral aberrant feelings may be lessened by reducing immune cells or their mediators²⁹. Innate and adaptive immune systems' inflammatory response is suppressed by regulatory T cells. Due to the decreased number of Treg cells in type 2 diabetes, the percentage and functionality of CD4⁺CD25⁺Foxp3⁺ and CD4⁺CD25⁺ regulatory T cells decline. Depletion of T-reg cells contributes to metabolic disorders including insulin resistance. Additionally, Treg cells are less able to generate anti-inflammatory cytokines such transforming growth factor- and interleukin-10, making them more prone to apoptosis: The ratio of Treg cells to T helper-1 and T helper-17 cells changes. The persistent low grade inflammatory status in type 2 diabetes is brought on by this insufficient anti-inflammatory response³⁰. Inflammation is now understood to be one of the fundamental mechanisms behind the onset and progression of kidney damage in the diabetic population³¹. Interleukin-17 and T helper 17 Patients with diabetes who have diabetic retinopathy have reduced generation of peripheral blood mononuclear cells. These have a bad relationship with BMI, the length of diabetes, and glycated haemoglobin levels³².

The variation in the expression level of pyroptosis-related genes, microRNA (miR) 146a-5p, miR-9-5p alleviates diabetes by inhibiting pyroptosis by targeting Toll-like receptors-2 and necrosis factor-κB1³³. Necrosis factor-κB inhibition further aggravates diabetic microangiopathy³⁴. A possible target for the treatment of type 2 diabetes is the inflammatory kinase (c-jun N-terminal kinase), which promotes both insulin resistance and beta cell dysfunction³⁵. TNF-, an inflammatory mediator, and the glycemic profile and insulin sensitivity in T2DM³⁶ are positively correlated. In addition to activating nitric oxide synthase-2, the production of cytokines also causes P450 enzyme activities to be directly inhibited and/or results in the downregulation of P450 proteins through protein instability. At least three innate immunity pathways, including the NLRP3 inflammasome, the cGAS (cyclic AMP-GMP synthase) pathway, and the TLR9 (Toll-like receptor 9) system, are activated by mitochondrial oxidant damage, including damage to mitochondrial DNA and mitochondrial generated oxidants³⁷. High levels of inﬂammatory marker, C-reactive protein, are related to insulin resistance and the metabolic syndrome, signifying a role for chronic low grade inﬂammation.

CONTRIBUTION OF INFLAMMATION TOWARDS METABOLIC SYNDROME:

The health promotion involves investigations³⁸ and methods³⁹ to achieve optimal health. Impaired glucose metabolism in diabetes mellitus causes elevated blood glucose levels and the generation of free radicals. Unfortunately, none of the current medications used to treat metabolic problems are without fault. The immune system mounts a type 2 response in conditions that are typically regulated by type 1 immunity when there is significant systemic stress. Inflammatory mediators or indicators produced by the immune system or adipose tissue are involved in the vascular problems of diabetes⁴⁰.

A prognostic factor used to assess the severity of illnesses associated to inflammation is the systemic immune-inflammation index, which is calculated as the platelet-neutrophil-lymphocyte ratio^41,42.Current medical therapies are ineffective for treating chronic pain caused by mechanically hypersensitive irritated nerves. The understanding that localised fat accumulation is a significant independent risk factor for the development of both diabetes and coronary heart disease has grown since the 1980s, to the point that the term "metabolic syndrome" has replaced the previous term "X syndrome" in medical terminology. The pro-thrombolytic and pro-inflammatory processes that underpin and may be at the root of the illness were added into the metabolic syndrome in addition to the states previously mentioned (abdominal obesity, dyslipidemia, hypertension, and glucose intolerance).

Interleukin-35 and Interleukin-10, two anti-inflammatory cytokines, are known to prevent acute and protracted endothelial cell activation caused by reactive oxygen species while protecting the trained immune system. This information might be used to develop inventive plans of action for combating inflammatory diseases⁴³. Linolenic acid (an anti-inflammatory fatty acid) is administered to Zucker fatty rats, who lack the leptin receptor, and this specifically reduces food intake and weight gain in the obese. Anti-CD20 antibodies are been developed to prevented lab mice at high risk for type 2 diabetes from developing the disorder. The treatment even restored their blood sugar to normal levels⁴⁴. Medications affecting the immune system have been demonstrated to be beneficial in people with type 2 diabetes. Immunosuppressant medications can prevent immune system cells, such as B cells, from attacking healthy tissue⁴⁵. Supplementing with wheat protein isolate is known to reduce oxidative and inflammatory stress, improve fasting glycemia, slow the advancement of other chronic illnesses, and help prevent the occurrence of diabetic complications⁴⁶. The potential targets of these upcoming medicines include inflammatory cytokines, oxidative stress, nuclear factor-kB (NF-kB), and the Janus Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway. A viable treatment should alter the complement system to reduce the abnormal levels while enabling the favourable players to continue supporting immune surveillance. The development of therapeutic modulators has received increased attention in recent years^47,48. It may be worthwhile to investigate the drugs' potential to delay or stop the evolution of metabolic diseases or associated consequences. Future research is necessary to evaluate the effectiveness of controlling complement activation in relation to the development of type 2 diabetes especially in rural mass⁴⁹,synergism^50,51 and optimum utilization of stevia^52,53.

CONCLUSION:

Research findings imply a direct causal link between tissue fatty acid distribution and inflammation, which has consequences for both insulin resistance and weight gain. In the next decades, it is anticipated that the burden of diabetes would significantly grow across the world along with the rise in obesity. Immunity is one of the most significant signs of diabetes, which significantly raises morbidity and death. Conventional therapies only partially guard against the onset of diabetes and its consequences. Therefore, it is obvious that novel approaches are needed to stop the onset and spread of this illness. The new methods should seek out therapeutic targets and methods for combating inflammation in addition to controlling established risk factors like hypertension and hyperglycemia. Future therapeutic strategies that have the power to control inflammatory processes may be helpful in the management or prevention of diabetes.

ACKNOWLEDGEMENT:

Authors are thankful to Respected Prof. S.W. Akhtar (Chancellor), Dr. Syed Nadeem Akhtar (Pro Chancellor), Prof. Javed Musarrat (Vice Chancellor) Integral University, Lucknow for outstanding support and guidance, (Manuscript communication Number: IU/R&D/2023-MCN0001815). Dr. Shom Prakash Kushwaha acknowledges Shri Parameshwar Foundation, Basti, India for Shri Parameshwar Foundation - Post Doctoral Fellowship (SPF/2022/APR/0A1).

CONFLICT OF INTEREST:

None.

REFERENCES:

1. Alam N. Agrawal OP. Rimpi. Alam P. Agrawal S. Kaushik M. Dhari JS. Sharma OP. Natural Immunoenhancers. Research J. Pharm. and Tech. 2011; 4(10): 1526-32.

2. Wu H. Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circulation Research. 2020; 126(11): 1549-64. doi:10.1161/CIRCRESAHA.119.315896

3. Morano AEVA. Dorneles GP. Peres A. Lira FS. The role of glucose homeostasis on immune function in response to exercise: The impact of low or higher energetic conditions. Journal of Cellular Physiology. 2020; 235(4): 3169-88. doi:10.1002/jcp.29228

4. Faas MM. de Vos P. Mitochondrial function in immune cells in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020; 1866(10): 165845. doi:10.1016/j.bbadis.2020.165845

5. Ashish A. Shah A. Pandey SJ. Interaction between oxidative stress and diabetes: a mini-review. J Diabetes Metab Disord Control. 2020; 7(2): 58-61.

6. Mahlangu T. Dludla PV. Nyambuya TM. et al. A systematic review on the functional role of Th1/Th2 cytokines in type 2 diabetes and related metabolic complications. Cytokine. 2020; 126: 154892. doi:10.1016/j.cyto.2019.154892

7. Moradi N. Fadaei R. Rashidbeygi E. et al. Evaluation of changing the pattern of CTRP5 and inflammatory markers levels in patients with coronary artery disease and type 2 diabetes mellitus. Archives of Physiology and Biochemistry. 2022; 128(4): 964-9. doi:10.1080/13813455.2020.1742164

8. Araújo LS. Silva MV. Silva CA. et al. Analysis of serum inflammatory mediators in type 2 diabetic patients and their influence on renal function. PLOS ONE. 2020; 15(3): e0229765. doi:10.1371/journal.pone.0229765

9. Al-Jobouri RF. Assessment of immune response in patients with type 2 Diabetes mellitus. ATMPH. 2020; 23(02): 51-57. doi:10.36295/ASRO.2020.2329

10. Olson NC. Doyle MF. Sitlani CM. et al. Associations of Innate and Adaptive Immune Cell Subsets With Incident Type 2 Diabetes Risk: The MESA Study. J Clin Endocrinol Metab. 2020; 105(3): e848-e857. doi:10.1210/clinem/dgaa036

11. Prattichizzo F. Giuliani A. Sabbatinelli J. et al. Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2020; 22(9): 1696-700.

12. Shim K. Begum R. Yang C. Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. 2020; 11(1): 1-12. doi:10.4239/wjd.v11.i1.1

13. Diedisheim M. Carcarino E. Vandiedonck C. Roussel R. Jean-François G. Venteclef N. Regulation of inflammation in diabetes: From genetics to epigenomics evidence. Molecular Metabolism. Published online June 27, 2020; 101041. doi:10.1016/j.molmet.2020.101041

14. Palella E. Cimino R. Pullano SA. et al. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. International Journal of Environmental Research and Public Health. 2020; 17(1): 300. doi:10.3390/ijerph17010300

15. Stubbs BJ. Newman JC. Ketogenic diet and adipose tissue inflammation—a simple story? Fat chance! Nat Metab. 2020; 2(1): 3-4. doi:10.1038/s42255-019-0164-2

16. Graves DT. Ding Z. Yang Y. The impact of diabetes on periodontal diseases. Periodontology 2000. 2020; 82(1): 214-24. doi:10.1111/prd.12318

17. RJPT - Comparative cytomorphometric analysis of oral mucosa in patients with Diabetes, patients with associated oral habits but with apparently normal mucosa and Control group. Accessed July 19, 2020. https://rjptonline.org/AbstractView.aspx?PID=2017-10-3-13

18. Gurung M. Li Z. You H. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020; 51: 102590. doi:10.1016/j.ebiom.2019.11.051

19. Massier L. Chakaroun R. Tabei S. et al. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut. Published online April 21, 2020; 69(10): 1796-806. doi:10.1136/gutjnl-2019-320118

20. Bekhbat M. Treadway MT. Goldsmith DR. et al. Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Brain, Behavior, and Immunity. 2020; 1; 88: 161-5. doi:10.1016/j.bbi.2020.03.015

21. Mistry KN. Dabhi BK. Joshi BB. Evaluation of oxidative stress biomarkers and inflammation in pathogenesis of diabetes and diabetic nephropathy. Indian Journal of Biochemistry and Biophysics (IJBB). 2020; 57(1): 45-50. http://14.139.47.23/index.php/IJBB/article/view/31769

22. Wu Y. Jia G. Wang B. et al. Fibroblast growth factor 1 ameliorates diabetes-induced splenomegaly via suppressing inflammation and oxidative stress. Biochemical and Biophysical Research Communications. 2020; 528(2): 249-255. doi:10.1016/j.bbrc.2020.05.145

23. Nyambuya TM. Dludla PV. Mxinwa V. Nkambule BB. T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus: A systematic review and meta-analysis. Clinical Immunology. 2020; 210: 108313. doi:10.1016/j.clim.2019.108313

24. Pinheiro-Machado E. Gurgul-Convey E. Marzec M. Immunometabolism in type 2 diabetes mellitus: tissue-specific interactions. aoms. Published online 2020. doi:10.5114/aoms.2020.92674

25. Alfieri DF. Lehmann MF. Flauzino T. et al. Immune-Inflammatory, Metabolic, Oxidative, and Nitrosative Stress Biomarkers Predict Acute Ischemic Stroke and Short-Term Outcome. Neurotox Res. 2020; 38(2): 330-343. doi:10.1007/s12640-020-00221-0

26. Di Conza G. Ho P-C. ER Stress Responses: An Emerging Modulator for Innate Immunity. Cells. 2020; 9(3): 695. doi:10.3390/cells9030695

27. Eizirik DL. Pasquali L. Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nature Reviews Endocrinology. 2020; 16(7): 349-362. doi:10.1038/s41574-020-0355-7

28. Zasłona Z. O’Neill LAJ. Cytokine-like Roles for Metabolites in Immunity. Molecular Cell. 2020; 78(5): 814-823. doi:10.1016/j.molcel.2020.04.002

29. Mert T. Sahin E. Yaman S. Sahin M. Effects of immune cell-targeted treatments result from the suppression of neuronal oxidative stress and inflammation in experimental diabetic rats. Naunyn-Schmiedeberg’s Arch Pharmacol. 2020; 393(7): 1293-1302. doi:10.1007/s00210-020-01871-9

30. Kartika R. Wibowo H. Impaired Function of Regulatory T Cells in Type 2 Diabetes Mellitus. Molecular and Cellular Biomedical Sciences. 2020; 4(1): 1-9. doi:10.21705/mcbs.v4i1.64

31. Donate-Correa J. Luis-Rodríguez D. Martín-Núñez E. et al. Inflammatory Targets in Diabetic Nephropathy. Journal of Clinical Medicine. 2020; 9(2): 458. doi:10.3390/jcm9020458

32. Ruiz de Morales JMG. Puig L. Daudén E. et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews. 2020; 19(1): 102429. doi:10.1016/j.autrev.2019.102429

33. Roshanravan N. Alamdari NM. Jafarabadi MA. et al. Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Cytokine. 2020; 131: 155101. doi:10.1016/j.cyto.2020.155101

34. Chen J. Tan W. Platelet activation and immune response in diabetic microangiopathy. Clinica Chimica Acta. 2020; 507: 242-247. doi:10.1016/j.cca.2020.04.042

35. Yung JHM. Giacca A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells. 2020; 9(3): 706. doi:10.3390/cells9030706

36. Bashir H. Ahmad Bhat S. Majid S. et al. Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India. Med J Islam Repub Iran. 2020;34:5. doi:10.34171/mjiri.34.5

37. Piantadosi CA. Mitochondrial DNA, oxidants, and innate immunity. Free Radical Biology and Medicine. 2020; 152: 455-461. doi:10.1016/j.freeradbiomed.2020.01.013

38. Kushwaha SP. Gupta SK. Kumar S. Phytochemical screening of aqueous extract derived from Stevia rebaudiana leaves, Musa acuminata fruits and Solanum lycopersicum fruits. International Journal of Botany Studies, 2021; 6(2): 510-512.

39. Ansari J. Kushwaha SP. Ansari VA. Singh K. Hasan SM. Agar well diffusion: A prominent method for in vitro screening of antimicrobials. International Journal of Botany Studies, 2021;6(5):836-839.

40. Biscetti F. Nardella E. Cecchini AL. Flex A. Landolfi R. Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk. Intern Emerg Med. 2020; 15(3): 381-393. doi:10.1007/s11739-019-02270-6

41. Yang Y-L. Wu C-H. Hsu P-F. et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. European Journal of Clinical Investigation. 2020; 50(5): e13230. doi:10.1111/eci.13230

42. Fest J. Ruiter R. Mulder M. et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer—A population-based cohort study. International Journal of Cancer. 2020; 146(3): 692-698. doi:10.1002/ijc.32303

43. Li X. Fang P. Sun Y. et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells. Redox Biology. 2020; 28: 101373. doi:10.1016/j.redox.2019.101373

44. Winer DA. Winer S. Shen L. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nature Medicine. 2011; 17(5): 610-617. doi:10.1038/nm.2353

45. Itariu BK. Stulnig TM. Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review. GER. 2014; 60(3): 189-196. doi:10.1159/000356747

46. Derosa G. D’Angelo A. Maffioli P. Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. Nutrition. 2020; 73: 110700. doi:10.1016/j.nut.2019.110700

47. Pratap R. Prakash Kushwaha S. Goel A. Ram VJ. An efficient synthesis of (E)-(2-arylpyrazino[1,2-a]pyrimidine-4-ylidene)acetonitriles and cyanomethyl appended pyrimidines. Tetrahedron Letters. 2007; 48(4): 549-553. doi:10.1016/j.tetlet.2006.11.136

48. Pratap R. Roy AD. Kushwaha SP. Goel A. Roy R. Ram VJ. Guanidine and amidine mediated synthesis of bridgehead triazaphenalenes, pyrimidines and pyridines through domino reactions. Tetrahedron Letters. 2007; 48(33): 5845-5849. doi:10.1016/j.tetlet.2007.06.073.

49. Kushwaha SP. Kumar P. Rawat SK. Abhishek. Parashar P. Hussain A. Singh P. Srivastava S. Tripathi K. A Preface Noesis Regarding General Health Awareness among the Rural Mass. Asian J. Pharm. Tech. 2012; 2(1): 12-14.

50. Kushwaha SP. Singh K. Kumar A. Hasan SM. Compassionate role of synergism in herbal formulations. International Journal of Biology, Pharmacy and Allied Sciences. 2022; 11(12): 5689-5895.

51. Salunkhe VR. Bhise SB. Synergistic Effect of Natural Sweetener on Antidiabetic Potential of Madhujeevan churna. Research J. Pharmacognosy and Phytochemistry 2009; 1(3): 204-208.

52. Gupta E. Mohammed A. Purwar S. Rizvi SI. Sundaram S. Diminution of oxidative stress in alloxan-induced diabetic rats by Stevia rebaudiana. Res. J. Pharmacognosy and Phytochem. 2017; 9(3): 158-166.

53. Sudha T. Devi DA. Kaviarasan L. Antihyperlipidemic effect of Stevia rebaudiana on Alloxan Induced Diabetic Rats. Asian J. Pharm. Tech. 2017; 7(4): 202-208.

Received on 06.01.2023 Revised on 16.12.2023

Accepted on 22.07.2024 Published on 20.01.2025

Available online from January 27, 2025

Research J. Pharmacy and Technology. 2025;18(1):33-38.

DOI: 10.52711/0974-360X.2025.00005

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.